Detalhe da pesquisa
1.
Research trends on vonoprazan-based therapy for Helicobacter pylori eradication: A bibliometric analysis from 2015 to 2023.
Helicobacter
; 28(5): e13012, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37515414
2.
Optimization of vonoprazan-amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study.
Helicobacter
; 27(4): e12896, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35466521
3.
Analysis of oral microbiota alterations induced by Helicobacter pylori infection and vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication.
Helicobacter
; 27(5): e12923, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36036087
4.
Research trends on artificial intelligence and endoscopy in digestive diseases: A bibliometric analysis from 1990 to 2022.
World J Gastroenterol
; 29(22): 3561-3573, 2023 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389238
5.
Altered Gut Microbiota and Short-Chain Fatty Acids After Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication.
Front Cell Infect Microbiol
; 12: 881968, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35719338
6.
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study.
Front Immunol
; 13: 1049908, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36726990